Residency · Residency · Internal Medicine

Acute Coronary Syndromes: STEMI vs. NSTEMI Management

Pathophysiology

Atherosclerotic Plaque Rupture and Erosion

Acute coronary syndromes arise predominantly from the disruption of a vulnerable atherosclerotic plaque, which triggers superimposed thrombosis. When a plaque ruptures, the lipid-rich necrotic core is exposed to circulating blood, setting off a cascade of platelet adhesion and coagulation activation. In roughly 25 to 40 percent of ACS events, the mechanism is plaque erosion rather than rupture -- the endothelium is denuded without frank disruption of the fibrous cap -- and this pattern is more common in younger patients and smokers. Whether the coronary artery becomes completely occluded by thrombus or only partially blocked determines the clinical presentation: complete occlusion produces a STEMI, while subtotal or transient occlusion leads to NSTEMI or unstable angina.

Myocardial Ischemia and Necrosis

The consequences of coronary occlusion follow a predictable sequence known as the ischemic cascade. Diastolic dysfunction appears first, followed by systolic wall motion abnormalities, then ECG changes, and finally chest pain. Necrosis itself advances in a wavefront pattern, beginning at the subendocardium and progressing transmurally over three to six hours. Even after blood flow is restored, reperfusion injury can inflict additional myocardial damage through reactive oxygen species, calcium overload, and inflammation.

Clinical Presentation

Typical Symptoms

The hallmark presentation is substernal chest pressure or heaviness, often described as a squeezing sensation or "an elephant sitting on my chest." Pain commonly radiates to the left arm, jaw, neck, back, or epigastrium and is accompanied by diaphoresis, nausea, and dyspnea. Duration is typically greater than 20 minutes, which is what distinguishes ACS from stable angina.

Atypical Presentations

Atypical presentations are more frequent in women, the elderly, and diabetic patients. These individuals may present primarily with dyspnea, fatigue, nausea, back pain, or even syncope rather than classic chest pain. Diabetic patients may experience a "silent MI" due to autonomic neuropathy, and inferior myocardial infarctions can produce epigastric pain that closely mimics gastrointestinal pathology.

Physical Examination Findings

The physical examination may be entirely normal. However, an S4 gallop suggests decreased ventricular compliance, while an S3 gallop or pulmonary rales indicates heart failure. A new mitral regurgitation murmur points to papillary muscle dysfunction or rupture. Hypotension accompanied by elevated jugular venous pressure raises concern for right ventricular involvement or cardiogenic shock. Diaphoresis, pallor, and anxiety are common nonspecific findings.

Diagnostic Workup

Electrocardiogram

An ECG must be obtained within 10 minutes of first medical contact. STEMI is diagnosed by new ST elevation at the J-point in two contiguous leads -- at least 1 mm in most leads, with higher thresholds in V2-V3 (at least 2 mm in men over 40, at least 2.5 mm in men under 40, and at least 1.5 mm in women). NSTEMI may show ST depression, T-wave inversions, or no acute changes at all.

Certain patterns deserve special attention. Posterior MI presents as ST depression in V1-V3 with tall R waves, and posterior leads (V7-V9) should be obtained. Right ventricular MI shows ST elevation in V1 alongside an inferior STEMI, prompting right-sided leads (V4R). A new or presumably new left bundle branch block is no longer considered a STEMI equivalent; instead, the Sgarbossa criteria (modified by Smith) should guide the assessment. Wellens syndrome, characterized by biphasic or deeply inverted T waves in V2-V3, signals critical LAD stenosis even when the patient is pain-free. De Winter T waves -- upsloping ST depression with tall peaked T waves in the precordial leads -- represent an LAD occlusion equivalent.

Cardiac Biomarkers

High-sensitivity troponin (hs-cTnI or hs-cTnT) is the gold standard for detecting myocardial injury. Serial measurements are taken at 0 and 3 hours, or at 0 and 1 hour using validated rapid rule-out protocols. Distinguishing acute myocardial injury from chronic troponin elevation requires a rise and/or fall pattern. Many conditions beyond ACS can elevate troponin, including myocarditis, pulmonary embolism, heart failure, sepsis, renal failure, takotsubo cardiomyopathy, and cardiac contusion. CK-MB, while less sensitive and specific, can help detect reinfarction because it clears faster than troponin.

Risk Stratification Tools

The TIMI score (0 to 7) predicts 14-day mortality and ischemic events in NSTEMI and unstable angina. The GRACE score provides more accurate in-hospital and 6-month mortality prediction and helps guide the timing of invasive strategy. The HEART score, validated for emergency department chest pain evaluation, is particularly useful for identifying very low-risk patients who may be candidates for early discharge.

Imaging

Echocardiography assesses left ventricular function, regional wall motion abnormalities, and mechanical complications. Coronary angiography provides definitive assessment of coronary anatomy. CT coronary angiography is useful for ruling out ACS in low-to-intermediate risk patients with negative troponins.

Management

STEMI Management

In STEMI, time is muscle. The goal is a door-to-balloon time of less than 90 minutes for primary percutaneous coronary intervention (PCI), or less than 120 minutes if transfer is required. Primary PCI is preferred over fibrinolysis whenever it can be performed within these time targets. When PCI is unavailable within 120 minutes, fibrinolysis should be administered within 30 minutes of arrival using agents such as tenecteplase (weight-based single bolus), alteplase, or reteplase. A pharmacoinvasive strategy -- fibrinolysis followed by transfer for angiography within 3 to 24 hours -- is used when timely primary PCI is not feasible. In most patients, culprit-lesion-only PCI is recommended acutely, though the CULPRIT-SHOCK trial favored initial culprit-only revascularization even in cardiogenic shock.

Antiplatelet and Antithrombotic Therapy

All patients receive an aspirin loading dose of 162 to 325 mg, followed by 81 mg daily indefinitely. For the P2Y12 inhibitor, ticagrelor 180 mg or prasugrel 60 mg are preferred over clopidogrel 600 mg in PCI-treated patients. Prasugrel is contraindicated in patients with prior stroke or TIA, and used cautiously in those under 60 kg or over age 75. Dual antiplatelet therapy (DAPT) is generally continued for 12 months post-ACS, though newer strategies may allow shortening to 3 to 6 months.

NSTEMI: Invasive vs. Conservative Strategy

An early invasive strategy with angiography within 24 hours is recommended for high-risk features, including a GRACE score above 140, recurrent angina, hemodynamic instability, elevated troponin, or dynamic ECG changes. A delayed invasive approach (24 to 72 hours) is reasonable for intermediate-risk patients. An ischemia-guided conservative strategy may be appropriate for low-risk patients with low TIMI or GRACE scores, negative troponin, and no recurrent symptoms. The ISCHEMIA trial demonstrated that in stable coronary artery disease with moderate-to-severe ischemia, an initial invasive strategy did not reduce death or MI compared to conservative management, though it did improve angina and quality of life.

Adjunctive Medical Therapy

Beta-blockers should be initiated within 24 hours when there are no contraindications such as heart failure, hypotension, or bradycardia. Oral metoprolol is preferred; intravenous beta-blockade in the acute setting should be avoided based on the COMMIT trial. ACE inhibitors or ARBs are started within 24 hours, especially for anterior MI, heart failure, or an ejection fraction below 40 percent. High-intensity statin therapy with atorvastatin 80 mg is initiated regardless of baseline lipids. An aldosterone antagonist (eplerenone or spironolactone) is added when the ejection fraction is 40 percent or less with heart failure symptoms or diabetes, as demonstrated by the EPHESUS trial. Nitrates provide relief for ongoing ischemic pain but are contraindicated in right ventricular infarction, hypotension, and recent PDE5 inhibitor use. Morphine should be used cautiously because it may reduce preload, mask symptoms, and has been associated with worse outcomes in some observational studies. NSAIDs other than aspirin and COX-2 inhibitors should be avoided in the post-MI period.

Complications

Mechanical Complications (typically days 3-7 post-MI)

Free wall rupture presents as sudden hemodynamic collapse with tamponade and requires emergent surgery. Ventricular septal rupture causes a new harsh holosystolic murmur with a step-up in oxygen saturation from the right atrium to the right ventricle. Papillary muscle rupture produces acute severe mitral regurgitation and is more common with inferior MI because the posteromedial papillary muscle has a single blood supply.

Arrhythmias

Ventricular fibrillation and tachycardia are the most common causes of pre-hospital death, with highest risk in the first 48 hours. Accelerated idioventricular rhythm is a common and generally benign reperfusion arrhythmia requiring no treatment. Heart block complicating inferior MI is usually transient and recovers, while complete heart block with anterior MI carries a worse prognosis.

Cardiogenic Shock

Cardiogenic shock occurs in 5 to 10 percent of STEMI patients. Emergent revascularization is the most important intervention. Vasopressor support with norepinephrine (preferred) and inotropes such as dobutamine or milrinone may be needed. Mechanical circulatory support options include IABP (which showed no mortality benefit in the IABP-SHOCK II trial), Impella, and ECMO.

Post-MI Pericarditis

Early pericarditis, occurring within days, results from direct local inflammation and is treated with aspirin while avoiding anticoagulation if possible. Dressler syndrome, appearing weeks to months later, is an autoimmune pericarditis treated with aspirin or NSAIDs plus colchicine.

<image> A detailed medical illustration showing a cross-section of a coronary artery with atherosclerotic plaque rupture. The illustration should depict the fibrous cap disruption, exposed lipid-rich necrotic core, platelet aggregation forming a thrombus, and the narrowed arterial lumen. Label the key components: endothelium, fibrous cap, lipid core, platelet thrombus, red blood cells, and smooth muscle cells. Use a color scheme with red for blood components, yellow for lipid core, and blue for the vessel wall layers. </image>

<image> A comparative 12-lead ECG diagram showing the key differences between STEMI and NSTEMI patterns. The left panel shows ST-elevation in leads II, III, aVF (inferior STEMI) with reciprocal ST depression in I and aVL. The right panel shows diffuse ST depression and T-wave inversions characteristic of NSTEMI. Include labels for each lead and annotations pointing out the diagnostic features. Clear, clean line tracings on a standard ECG grid background. </image>

<image> A clinical algorithm flowchart for ACS management. Starting with "Chest Pain Presentation" at the top, branching based on ECG findings into STEMI pathway (leading to primary PCI vs fibrinolysis decision based on time and availability) and NSTE-ACS pathway (leading to risk stratification with GRACE/TIMI scores, then early invasive vs conservative strategy). Include time targets (door-to-balloon <90 min, door-to-needle <30 min) and key decision points. Use color coding: red for STEMI pathway, orange for high-risk NSTEMI, green for low-risk pathway. </image>

<image> An anatomical diagram of the heart showing coronary artery territories and their corresponding ECG lead distributions. Display the LAD territory (anterior wall, leads V1-V4), the RCA territory (inferior wall, leads II, III, aVF), and the LCx territory (lateral wall, leads I, aVL, V5-V6). Include the posterior and right ventricular territories with their special lead positions (V7-V9, V4R). The heart should be shown in anterior view with transparent walls revealing the territories as color-coded regions. </image>

Clinical Pearls

Every patient presenting with possible ACS should receive a 12-lead ECG within 10 minutes; if the initial tracing is non-diagnostic but clinical suspicion persists, the ECG should be repeated every 15 to 30 minutes. Posterior MI, which appears as isolated ST depression in V1-V3, is a STEMI equivalent that requires emergent reperfusion -- always consider obtaining posterior leads. Right ventricular infarction (identified by ST elevation in V4R) complicates roughly 40 percent of inferior STEMIs, and because these patients are preload-dependent, nitrates and diuretics must be avoided. High-sensitivity troponin offers excellent negative predictive value with rapid rule-out protocols, but clinicians must remember that many non-ACS conditions also elevate troponin. Type 2 MI, caused by supply-demand mismatch without plaque rupture, is common in hospitalized patients and does not benefit from an invasive strategy -- treating the underlying cause is the priority. In cocaine-associated ACS, beta-blockers should be avoided due to the risk of unopposed alpha-stimulation; management relies on benzodiazepines, nitrates, and calcium channel blockers. DAPT compliance must be assessed and documented, especially regarding the risk of stent thrombosis if the P2Y12 inhibitor is discontinued prematurely. The post-MI care bundle includes DAPT, high-intensity statin, beta-blocker, ACE inhibitor or ARB, and referral to cardiac rehabilitation.

References

• Amsterdam EA, et al. 2014 AHA/ACC Guideline for the Management of Patients with NSTE-ACS. Circulation. 2014.
• O'Gara PT, et al. 2013 ACCF/AHA Guideline for the Management of STEMI. Circulation. 2013.
• Lawton JS, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization. Circulation. 2022.
• ISCHEMIA Trial: Maron DJ, et al. Initial Invasive or Conservative Strategy for Stable Coronary Disease. NEJM. 2020.
• IABP-SHOCK II Trial: Thiele H, et al. Intra-aortic Balloon Support for Myocardial Infarction with Cardiogenic Shock. NEJM. 2012.
• CULPRIT-SHOCK Trial: Thiele H, et al. PCI Strategies in Patients with Acute MI and Cardiogenic Shock. NEJM. 2017.
• PLATO Trial (ticagrelor vs clopidogrel): Wallentin L, et al. NEJM. 2009.
• TRITON-TIMI 38 (prasugrel vs clopidogrel): Wiviott SD, et al. NEJM. 2007.
• EPHESUS Trial (eplerenone post-MI): Pitt B, et al. NEJM. 2003.

Read this lecture as Markdown